

# WHO Position Paper on Measles Vaccines, Aug 2009

## References

### Epidemiology

WHO: Progress in global measles control and mortality reduction, 2000–2007. *Wkly Epidemiol Rec* 2008; 83, 441–448.

WHO: Measles global annual reported incidence and MCV coverage, 1980-2003. <http://www.who.int/vaccines-surveillance/graphics/htmls/IncMeas.htm> (last accessed 10 January 2006).

*Enquselassie F, Ayele W, Dejene A, Messele T, Abebe A, Cutts FT, Nokes DJ.* Seroepidemiology of measles in Addis Ababa, Ethiopia: implications for control through vaccination. *Epidemiol Infect.* 2003 Jun;130(3):507-19.

*Samb B, Aaby P, Whittle HC, Seck AM, Rahman S, Bennett J, Markowitz L, Simondon F.* Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. *Pediatr Infect Dis J.* 1995 Mar;14(3):203-9.

*Campbell C, Levin S, Humphreys P, Walop W, Brannan R.* Subacute sclerosing panencephalitis: results of the Canadian Paediatric Surveillance Program and review of the literature. *BMC Pediatr.* 2005 Dec 15;5:47.

### Measles viruses

*Rota PA, Featherstone DA, Bellini WJ.* Molecular epidemiology of measles virus. *Curr Top Microbiol Immunol.* 2009;330:129-50.

*Schneider-Schaulies S, Schneider-Schaulies J.* Measles virus-induced immunosuppression. *Curr Top Microbiol Immunol.* 2009;330:243-69.

*Atrasheuskaya AV, Kulak MV, Neverov AA, Rubin S, Ignatyev GM.* Measles cases in highly vaccinated population of Novosibirsk, Russia, 2000-2005. *Vaccine.* 2008 Apr 16;26(17):2111-8.

*Okafuji T, Okafuji T, Fujino M, Nakayama T.* Current status of measles in Japan: molecular and seroepidemiological studies. *J Infect Chemother.* 2006 Dec;12(6):343-8.

## Measles disease

*Griffin DE, Oldstone MM.* Measles. Pathogenesis and control. Introduction. *Curr Top Microbiol Immunol.* 2009;330:1 (No summary)

*Wolfson LJ, Grais RF, Luquero FJ, Birmingham ME, Strebel PM.* Estimates of measles case fatality ratios: a comprehensive review of community-based studies. *Int J Epidemiol.* 2009 Feb;38(1):192-205.

*Nandy R, Handzel T, Zaneidou M, Biey J, Cuddy RZ, Perry R, Strebel P, Cairns L.* Case-fatality rate during a measles outbreak in eastern Niger in 2003. *Clin Infect Dis.* 2006 Feb 1;42(3):322-8.

*Perry RT, Halsey NA.* The clinical significance of measles: a review. *J Infect Dis.* 2004 May 1;189 Suppl 1:S4-16.

*Huiming Y, Chaomin W, Meng M.* Vitamin A for treating measles in children. *Cochrane Database Syst Rev.* 2005 Oct 19;(4):CD001479.

*Glasziou PP, Mackerras DE.* Vitamin A supplementation in infectious diseases: a meta-analysis. *BMJ.* 1993 Feb 6;306(6874):366-70.

## Measles vaccines

*Strebel PM, Papania MJ, Halsey NA.* Measles vaccine. In: Plotkin SA, Orenstein WA, eds. *Vaccines.* 4<sup>th</sup> ed. Philadelphia, Pa: Elsevier Inc; 2004:406-407.

WHO/UNICEF measles vaccination coverage information:  
<http://www.who.int/vaccines-surveillance/graphics/htmls/IncMeas.htm>

## Immunogenicity

*Saffar MJ, Ajami A, Khalilian AR, Saffar H.* The impact of maternal measles-rubella-immunization on the 12-month-old infant's immune response to measles-mumps-rubellavaccine immunogenicity. *Eur J Clin Microbiol Infect Dis.* 2009 Jul;28(7):845-7.

*Gillet Y, Habermehl P, Thomas S, Eymin C, Fiquet A.* Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and

a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. *BMC Med.* 2009 Apr 14;7:16.

*Kurubi J, Vince J, Ripa P, Tefuarani N, Riddell M, Duke T.* Immune response to measles vaccine in 6 month old infants in Papua New Guinea. *Trop Med Int Health.* 2009 Feb;14(2):167-73.

*Gillet Y, Steri GC, Behre U, Arsène JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, Willems P.* Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. *Vaccine.* 2009 Jan 14;27(3):446-53.

*Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P.* Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. *Pediatr Infect Dis J.* 2008 Aug;27(8):724-30.

*Dhillon S, Curran MP.* Live attenuated measles, mumps, rubella, and varicella zoster virus vaccine (Priorix-Tetra). *Paediatr Drugs.* 2008;10(5):337-47.

*Goh P, Lim FS, Han HH, Willems P.* Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. *Infection.* 2007 Oct;35(5):326-33.

*Zepp F, Behre U, Kindler K, Laakmann KH, Pankow-Culot H, Mannhardt-Laakmann W, Beckers F, Descamps D, Willems P.* Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. *Eur J Pediatr.* 2007 Aug;166(8):857-64.

*Vesikari T, Baer M, Willems P.* Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. *Pediatr Infect Dis J.* 2007 Feb;26(2):153-8.

*Black SB, Cimino CO, Hansen J, Lewis E, Ray P, Corsaro B, Graepel J, Laufer D.* Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. *Pediatr Infect Dis J.* 2006 Apr;25(4):306-11.

*Feiterna-Sperling C, Brönnimann R, Tischer A, Stettler P, Durrer P, Gaedicke G.* Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children. *Pediatr Infect Dis J.* 2005 Dec;24(12):1083-8.

*John S, Lalitha G, George K, Joseph A.* Serological response to early measles vaccination. *J Trop Pediatr.* 2004 Jun;50(3):175-7.

*Paunio M, Hedman K, Davidkin I, Peltola H.* IgG avidity to distinguish secondary from primary measles vaccination failures: prospects for a more effective global measles elimination strategy. *Expert Opin Pharmacother.* 2003 Aug;4(8):1215-25.

*Pannuti CS, Morello RJ, Moraes JC, Curti SP, Afonso AM, Camargo MC, Souza VA.* Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic. *Clin Diagn Lab Immunol.* 2004 Jan;11(1):119-22.

*Stück B, Stehr K, Bock HL.* Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. *Asian Pac J Allergy Immunol.* 2002 Jun;20(2):113-20.

*Paunio M, Hedman K, Davidkin I, Valle M, Heinonen OP, Leinikki P, Salmi A, Peltola H.* Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. *Epidemiol Infect.* 2000 Apr;124(2):263-71.

*Pannuti CS, Moraes JC, Souza VA, Camargo MC, Hidalgo NT.* Measles antibody prevalence after mass immunization in São Paulo, Brazil. *Bull World Health Organ.* 1991;69(5):557-60.

## Efficacy-Effectiveness

*Sheppard V, Forssman B, Ferson MJ, Moreira C, Campbell-Lloyd S, Dwyer DE, McAnulty JM.* Vaccine failures and vaccine effectiveness in children during measles outbreaks in New South Wales, March-May 2006. *Commun Dis Intell.* 2009 Mar;33(1):21-6.

*Velicko I, Müller LL, Pebody R, Gergonne B, Aidyralieva C, Kostiuhenko N, Spika JS.* Nationwide measles epidemic in Ukraine: the effect of low vaccine effectiveness. *Vaccine.* 2008 Dec 9;26(52):6980-5.

Wichmann O, Hellenbrand W, Sagebiel D, Santibanez S, Ahlemeyer G, Vogt G, Siedler A, van Treeck U. Large measles outbreak at a German public school, 2006. *Pediatr Infect Dis J*. 2007 Sep;26(9):782-6.

Elliman D, Sengupta N, El Bashir H, and Bedford H. Child health. Measles, mumps, and rubella prevention. *Clinical Evidence*. Web publication date: 01 Feb 2007. [http://clinicalevidence.bmj.com/ceweb/conditions/chd/0316/0316\\_II.jsp](http://clinicalevidence.bmj.com/ceweb/conditions/chd/0316/0316_II.jsp)

Kremer JR, Schneider F, Muller CP. Waning antibodies in measles and rubella vaccinees—a longitudinal study. *Vaccine*. 2006 Mar 24;24(14):2594-601.

Marin M, Nguyen HQ, Langidrik JR, Edwards R, Briand K, Papania MJ, Seward JF, LeBaron CW. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy. *Clin Infect Dis*. 2006 Feb 1;42(3):315-9.

Yeung LF, Lurie P, Dayan G, Eduardo E, Britz PH, Redd SB, Papania MJ, Seward JF. A limited measles outbreak in a highly vaccinated US boarding school. *Pediatrics*. 2005 Dec;116(6):1287-91.

Demicheli V, Jefferson T, Rivetti A, Price D. Vaccines for measles, mumps and rubella in children. *Cochrane Database Syst Rev*. 2005 Oct 19;(4): CD004407.

Borus PK, Cumberland P, Sonoiya S, Kombich J, Tukei PM, Cutts FT. Measles trends and vaccine effectiveness in Nairobi, Kenya. *East Afr Med J*. 2003 Jul;80(7):361-4.

Akramuzzaman SM, Cutts FT, Hossain MJ, Wahedi OK, Nahar N, Islam D, Shaha NC, Mahalanabis D. Measles vaccine effectiveness and risk factors for measles in Dhaka, Bangladesh. *Bull World Health Organ*. 2002;80(10):776-82.

Hennessey KA, Ion-Nedelcu N, Craciun MD, Toma F, Wattigney W, Strebel PM. Measles epidemic in Romania, 1996-1998: assessment of vaccine effectiveness by case-control and cohort studies. *Am J Epidemiol*. 1999 Dec 1;150(11):1250-7.

Whittle HC, Aaby P, Samb B, Jensen H, Bennett J, Simondon F. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa. *Lancet*. 1999;353:98-101.

Mossong J, Nokes DJ, Edmunds WJ, Cox MJ, Ratnam S, Muller CP. Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity. *Am J Epidemiol*. 1999;150:1238-1249.

*Lee MS, Lee LL, Chen HY, Wu YC, Horng CB.* Post mass-immunization measles outbreak in Taoyuan County, Taiwan: dynamics of transmission, vaccine effectiveness, and herd immunity. *Int J Infect Dis.* 1998-1999 Winter;3(2):64-9.

*Sutcliffe PA, Rea E.* Outbreak of measles in a highly vaccinated secondary school population. *CMAJ.* 1996 Nov 15;155(10):1407-13.

*Kaninda AV, Legros D, Jataou IM, Malfait P, Maisonneuve M, Paquet C, Moren A.* Measles vaccine effectiveness in standard and early immunization strategies, Niger, 1995. *Pediatr Infect Dis J.* 1998 Nov;17(11):1034-9.

*Singh J, Datta KK.* Measles vaccine efficacy in India: a review. *J Commun Dis.* 1997 Mar;29(1):47-56.

*Güriş D, McCready J, Watson JC, Atkinson WL, Heath JL, Bellini WJ, Polloi A.* Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus. *Pediatr Infect Dis J.* 1996 Dec;15(12):1082-6.

*Aaby P, Samb B, Simondon F, Seck AM, Knudsen K, Whittle H.* Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. *BMJ.* 1995 Aug 19;311(7003):481-5

*Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, Cantell K.* The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. *N Engl J Med.* 1994 Nov 24;331(21):1397-402

*Herceg A, Passaris I, Mead C.* An outbreak of measles in a highly immunised population: immunisation status and vaccine efficacy. *Aust J Public Health.* 1994 Sep;18(3):249-52.

*Yuan L.* Measles outbreak in 31 schools: risk factors for vaccine failure and evaluation of a selective revaccination strategy. *CMAJ.* 1994 Apr 1;150(7):1093-8.

*Malfait P, Jataou IM, Jollet MC, Margot A, De Benoist AC, Moren A.* Measles epidemic in the urban community of Niamey: transmission patterns, vaccine efficacy and immunization strategies, Niger, 1990 to 1991. *Pediatr Infect Dis J.* 1994 Jan;13(1):38-45.

*Hersh BS, Markowitz LE, Hoffman RE, Hoff DR, Doran MJ, Fleishman JC, Preblud SR, Orenstein WA.* A measles outbreak at a college with a prematriculation immunization requirement. *Am J Public Health.* 1991 Mar;81(3):360-4.

Koenig MA, Khan MA, Wojtyniak B, Clemens JD, Chakraborty J, Fauveau V, Phillips JF, Akbar J, Barua US. Impact of measles vaccination on childhood mortality in rural Bangladesh. *Bull World Health Organ.* 1990;68(4):441-7.

Anonymous. Vaccination against measles: clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. Second report to the medical research council by the measles vaccines committee. *BMJ* 1968;2:449-452.

Marin M, Nguyen HQ, Langidrik JR, Edwards R, Briand K, Papania MJ, Seward JF, LeBaron CW. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy. *Clin Infect Dis.* 2006 Feb 1;42(3):315-9. Miller C. Live measles vaccine: a 21 year follow up. *Br Med J (Clin Res Ed).* 1987 Jul 4;295(6589):22-4.

## Duration of protection/persistence of antibodies

Atrasheuskaya AV, Kulak MV, Neverov AA, Rubin S, Ignatyev GM. Measles cases in highly vaccinated population of Novosibirsk, Russia, 2000-2005. *Vaccine.* 2008 Apr 16;26(17):2111-8.

Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. *J Infect Dis.* 2008 Apr 1;197(7):950-6.

LeBaron CW, Beeler J, Sullivan BJ, Forghani B, Bi D, Beck C, Audet S, Gargiullo P. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. *Arch Pediatr Adolesc Med.* 2007 Mar;161(3):294-301.

Kremer JR, Schneider F, Muller CP. Waning antibodies in measles and rubella vaccines—a longitudinal study. *Vaccine.* 2006;24: 2594-2601.

Dine MS, Hutchins SS, Thomas A, Williams I, Bellini WJ, Redd SC. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination. *J Infect Dis.* 2004 May 1;189 Suppl 1:S123-30.

Hirose M, Hidaka Y, Miyazaki C, Ueda K, Yoshikawa H. Five cases of measles secondary vaccine failure with confirmed seroconversion after live measles vaccination. *Scand J Infect Dis.* 1997;29(2):187-90.

*Güriş D, McCreedy J, Watson JC, Atkinson WL, Heath JL, Bellini WJ, Polloi A.* Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus. *Pediatr Infect Dis J.* 1996 Dec;15(12):1082-6.

*Anders JF, Jacobson RM, Poland GA, Jacobsen SJ, Wollan PC.* Secondary failure rates of measles vaccines: a metaanalysis of published studies. *Pediatr Infect Dis J.* 1996 Jan;15(1):62-6.

*Ramsay ME, Moffatt D, O'Connor M.* Measles vaccine: a 27-year follow-up. *Epidemiol Infect.* 1994 Apr;112(2):409-12.

*Hersh BS, Markowitz LE, Hoffman RE, Hoff DR, Doran MJ, Fleishman JC, Preblud SR, Orenstein WA.* A measles outbreak at a college with a prematriculation immunization requirement. *Am J Public Health.* 1991 Mar;81(3):360-4.

*Hutchins SS, Markowitz LE, Mead P, Mixon D, Sheline J, Greenberg N, Preblud SR, Orenstein WA, Hull HF.* A school-based measles outbreak: the effect of a selective revaccination policy and risk factors for vaccine failure. *Am J Epidemiol.* 1990 Jul;132(1):157-68.

*Markowitz LE, Preblud SR, Fine PEM, Orenstein WA.* Duration of live measles vaccine-induced immunity. *Pediatr Infect Dis J.* 1990;9:101-110.

*Mathias RG, Meekison WG, Arcand TA, Schechter MT.* The role of secondary vaccine failures in measles outbreaks. *Am J Public Health.* 1989 Apr;79(4):475-8.

*Miller C.* Live measles vaccine: a 21 year follow up. *Br Med J (Clin Res Ed).* 1987 Jul 4;295(6589):22-4.

*Nkowane BM, Bart SW, Orenstein WA, Baltier M.* Measles outbreak in a vaccinated school population: epidemiology, chains of transmission and the role of vaccine failures. *Am J Public Health.* 1987 Apr;77(4):434-8.

*Faust HS, Thompson FE.* Age at and time since vaccination during a measles outbreak in a rural community. *Am J Dis Child.* 1983 Oct;137(10):977-80.

## One versus two doses

*Lynn TV, Beller M, Funk EA, Middaugh JP, Ritter D, Rota PA, Bellini WJ, Torok TJ.* Incremental effectiveness of 2 doses of measles-containing vaccine compared with 1 dose among high school students during an outbreak. *J Infect Dis.* 2004 May 1;189 Suppl 1:S86-90.

*Thomas A, Xu D, Wooten K, Morrow B, Redd S.* Timing and effectiveness of requirements for a second dose of measles vaccine. *Pediatr Infect Dis J.* 1999 Mar;18(3):266-70.

*Davidkin I, Valle M.* Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. *Vaccine.* 1998 Dec;16(20):2052-7.

*Bartoloni A, Cutts FT, Guglielmetti P; et al.* Response to measles revaccination among Bolivian school-aged children. *Trans R Soc Trop Med Hyg.* 1997;91:716-718.

*Poland GA, Jacobson RM, Thampy AM, Colbourne SA, Wollan PC, Lipsky JJ, Jacobsen SJ.* Measles reimmunization in children seronegative after initial immunization. *JAMA.* 1997 Apr 9;277(14):1156-8

*Cohn ML, Robinson ED, Faerber M; et al.* Measles vaccine failures: lack of sustained measles-specific immunoglobulin G responses in revaccinated adolescents and young adults. *Pediatr Infect Dis J.* 1994;13:34-38.

*Ozanne G, d'Halewyn MA.* Secondary immune response in a vaccinated population during a large measles epidemic. *J Clin Microbiol.* 1992 Jul;30(7):1778-82

## HIV and measles vaccination

WHO: Global Advisory Committee on Vaccine Safety, report of meeting held 17-18 June 2009. *Wkly Epidemiol Rec.* 2009; 84, 325-332.

*Lowther SA, Curriero FC, Kalish BT, Shields TM, Monze M, Moss WJ.* Population immunity to measles virus and the effect of HIV-1 infection after a mass measles vaccination campaign in Lusaka, Zambia: a cross-sectional survey. *Lancet.* 2009 Mar 21;373(9668):1025-32.

*Helfand RF, Witte D, Fowlkes A, Garcia P, Yang C, Fudzulani R, Walls L, Bae S, Strebel P, Broadhead R, Bellini WJ, Cutts F.* Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi. *J Infect Dis.* 2008 Nov 15;198(10):1457-65

Scott S, Mossong J, Moss WJ, Cutts FT, Cousens S. Predicted impact of the HIV-1 epidemic on measles in developing countries: results from a dynamic age-structured model. *Int J Epidemiol*. 2008 Apr;37(2):356-67.

Tejiokem MC, Gouandjika I, Béniguel L, Zanga MC, Tene G, Gody JC, Njamkepo E, Kfutwah A, Penda I, Bilong C, Rousset D, Pouillot R, Tangy F, Baril L. HIV-infected children living in Central Africa have low persistence of antibodies to vaccines used in the Expanded Program on Immunization. *PLoS ONE*. 2007 Dec 5;2(12):e1260.

Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. *Clin Infect Dis*. 2007 Sep 1;45(5):637-42

Moss WJ, Scott S, Mugala N, Ndhlovu Z, Beeler JA, Audet SA, Ngala M, Mwangala S, Nkonga-Mwangilwa C, Ryon JJ, Monze M, Kasolo F, Quinn TC, Cousens S, Griffin DE, Cutts FT. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. *J Infect Dis*. 2007 Aug 1;196(3):347-55.

Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaaijer H, Kuijpers TW. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. *Pediatrics*. 2006 Aug;118(2):e315-22.

Melvin AJ, Mohan KM. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. *Pediatrics*. 2003 Jun;111(6 Pt 1):e641-4.

Goon P, Cohen B, Jin L, Watkins R, Tudor-Williams G. MMR vaccine in HIV-infected children—potential hazards? *Vaccine*. 2001 Jul 16;19(28-29):3816-9.

Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. *Clin Infect Dis*. 2001 Apr 1;32(7):1090-4.

Moss WJ, Cutts F, Griffin DE. Implications of the human immunodeficiency virus epidemic for control and eradication of measles. *Clin Infect Dis*. 1999 Jul;29(1):106-12.

*Anders JF, Jacobson RM, Poland GA, Jacobsen SJ, Wollan PC.* Secondary failure rates of measles vaccines: a metaanalysis of published studies. *Pediatr Infect Dis J.* 1996 Jan;15(1):62-6.

*Breña AE, Cooper ER, Cabral HJ, Pelton SI.* Antibody response to measles and rubella vaccine by children with HIV infection. *J Acquir Immune Defic Syndr.* 1993 Oct;6(10):1125-9.

*Lepage P, Dabis F, Msellati P, Hitimana DG, Stevens AM, Mukamabano B, Van Goethem C, Van de Perre P.* Safety and immunogenicity of high-dose Edmonston-Zagreb measles vaccine in children with HIV-1 infection. A cohort study in Kigali, Rwanda. *Am J Dis Child.* 1992 May;146(5):550-5.

## Safety

WHO: Global Advisory Committee on Vaccine Safety, report of meeting held 17-18 June 2009. *Wkly Epidemiol Rec.* 2009; 84, 325-332.

*Halperin SA, Ferrera G, Scheifele D, Predy G, Stella G, Cuccia M, Douha M, Willems P.* Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. *Vaccine.* 2009 May 5;27(20):2701-6.

*Jefferson T, Price D, Demicheli V, Bianco E;* European Research Program for Improved Vaccine Safety Surveillance (EUSAFEVAC) Project. Unintended events following immunization with MMR: a systematic review. *Vaccine.* 2003 Sep 8;21(25-26):3954-60

*Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P.* Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. *Pediatr Infect Dis J.* 2008 Aug;27(8):724-30.

*Gatchalian S, Yao Y, Zhou B, Zhang L, Yoksan S, Kelly K, Neuzil KM, Yaïch M, Jacobson J.* Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. *Vaccine.* 2008 Apr 24;26(18):2234-41.

Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. *MMWR Morb Mortal Wkly Rep.* 2008 Mar 14;57(10):258-60.

France EK, Glanz J, Xu S, Hambidge S, Yamasaki K, Black SB, Marcy M, Mullooly JP, Jackson LA, Nordin J, Belongia EA, Hohman K, Chen RT, Davis R; Vaccine Safety Datalink Team. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. *Pediatrics*. 2008 Mar;121(3):e687-92.

Goh P, Lim FS, Han HH, Willems P. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. *Infection*. 2007 Oct;35(5):326-33.

Vesikari T, Baer M, Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. *Pediatr Infect Dis J*. 2007 Feb;26(2):153-8.

WHO Immunization safety. Adverse events following immunization.  
[http://www.who.int/immunization\\_safety/publications/aefi/en/](http://www.who.int/immunization_safety/publications/aefi/en/)

Last update: 12 April 2006

Feiterna-Sperling C, Brönnimann R, Tischer A, Stettler P, Durrer P, Gaedicke G. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children. *Pediatr Infect Dis J*. 2005 Dec;24(12):1083-8.

De Stefano F, Bhasin TK, Thompson WW, et al. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study metropolitan Atlanta. *Pediatrics* 2004;113:259-266.

Maher JE, Mullooly JP, Drew L, et al. Infant vaccinations and childhood asthma among full-term infants. *Pharmacoepidemiol Drug Saf* 2004;13:1-9.

McKeever TM, Lewis SA, Smith C, et al. Vaccination and allergic disease: a birth cohort study. *Am J Public Health* 2004;94:985-989.

Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. *JAMA* 2004;292:351-357.

Ki M, Park T, Yi SG, et al. Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case-crossover design. *Am J Epidemiol* 2003;157:158-165.

*Stück B, Stehr K, Bock HL.* Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. *Asian Pac J Allergy Immunol.* 2002 Jun;20(2):113-20.

*Madsen KM, Hviid A, Vestergaard M, et al.* A population-based study of measles, mumps, and rubella vaccination and autism. *N Engl J Med* 2002;347:1477-1482.

*Shinefield HR, Black SB, Staehle BO, Matthews H, Adelman T, Ensor K, Li S, Chan I, Heyse J, Waters M, Chan CY, Vessey SJ, Kaplan KM, Kuter BJ; Kaiser Permanente Medical Team for Varivax.* Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. *Pediatr Infect Dis J.* 2002 Jun;21(6):555-61.

*Barlow WE, Davis RL, Glasser JW.* The risk of seizures after receipt of whole cell pertussis or measles mumps and rubella vaccine. *N Engl J Med* 2001;345:656-661.

*Carapetis JR, Curtis N.* MMR immunisation. True anaphylaxis to MMR vaccine is extremely rare. *BMJ.* 2001 October 13; 323(7317): 869.

*Virtanen M, Peltola H, Paunio M, et al.* Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. *Pediatrics* 2000;106:e62.

*Patja A, Davidkin I, Kurki T, et al.* Serious adverse events after measles-mumps-rubella vaccination during a fourteen year prospective follow up. *Pediatr Infect Dis J* 2000;19:1127-1134.

*Duclos P, Ward BJ.* Measles vaccines: a review of adverse events. *Drug Saf.* 1998 Dec;19(6):435-54.

## Cost-effectiveness

*Uzicanin A, Zhou F, Eggers R, Webb E, Strebel P.* Economic analysis of the 1996-1997 mass measles immunization campaigns in South Africa. *Vaccine.* 2004 Sep 3;22(25-26):3419-26.

*Zhou F, Reef S, Massoudi M, Papania MJ, Yusuf HR, Bardenheier B, Zimmerman L, McCauley MM.* An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States. *J Infect Dis.* 2004 May 1;189 Suppl 1:S131-45.

*Dayan GH, Cairns L, Sangrujee N, Mtonga A, Nguyen V, Strebel P.* Cost-effectiveness of three different vaccination strategies against measles in Zambian children. *Vaccine.* 2004 Jan 2;22(3-4):475-84.

*Beutels P, Gay NJ.* Economic evaluation of options for measles vaccination strategy in a hypothetical Western European country. *Epidemiol Infect.* 2003 Apr;130(2):273-83.

*Acharya A, Diaz-Ortega JL, Tambini G, de Quadros C, Arita I.* Cost-effectiveness of measles elimination in Latin America and the Caribbean: a prospective analysis. *Vaccine.* 2002 Sep 10;20(27-28):3332-41.

*Zwanziger J, Szilagyi PG, Kaul P.* Evaluating the benefits of increasing measles immunization rates. *Health Serv Res.* 2001 Oct;36(5):885-909.

*Pelletier L, Chung P, Duclos P, Manga P, Scott J.* A benefit-cost analysis of two-dose measles immunization in Canada. *Vaccine.* 1998 May-Jun;16(9-10):989-96.

*Shiell A, Jorm LR, Carruthers R, Fitzsimmons GJ.* Cost-effectiveness of measles outbreak intervention strategies. *Aust N Z J Public Health.* 1998 Feb;22(1):126-32.

## Policy issues

*John S, Sanghi S, Prasad S, Bose A, George K.* Two doses of measles vaccine: are some states in India ready for it? *J Trop Pediatr.* 2009 Aug;55(4):253-6.

*Wood JG, Gidding HF, Heywood A, Macartney K, McIntyre PB, Macintyre CR.* Potential impacts of schedule changes, waning immunity and vaccine uptake on measles elimination in Australia. *Vaccine.* 2009 Jan 7;27(2):313-8.

Centers for Disease Control and Prevention (CDC). Progress toward measles elimination—European Region, 2005--2008. *MMWR Morb Mortal Wkly Rep.* 2009 Feb 20;58(6):142-5.

*Orenstein WA, Hinman AR, Strebel PJ.* Measles: the need for 2 opportunities for prevention. *Clin Infect Dis.* 2006;42:320-321.

*Centers for Disease Control and Prevention.* Progress in reducing global measles deaths, 1999-2004. *MMWR Morb Mortal Wkly Rep.* 2006;55:247-249.

*Parker AA, Staggs W, Dayan GH, Ortega-Sánchez IR, Rota PA, Lowe L, Boardman P, Teclaw R, Graves C, LeBaron CW.* Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. *N Engl J Med.* 2006 Aug 3;355(5):447-55.

*King A, Varughese P, De Serres G, Tipples GA, Waters J; Working Group on Measles Elimination.* Measles elimination in Canada. *J Infect Dis.* 2004 May 1;189 Suppl 1:S236-42.

*De Quadros CA, Izurieta H, Carrasco P, Brana M, Tambini G.* Progress toward measles eradication in the region of the Americas. *J Infect Dis.* 2003 May 15;187 Suppl 1:S102-10.

*Pebody RG, Gay NJ, Hesketh LM; et al.* Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. *Vaccine.* 2002;20:1134-1140.

*Salmon DA, Haber M, Gangarosa EJ, Phillips L, Smith NJ, Chen RT.* Health consequences of religious and philosophical exemptions from immunization laws: individual and societal risk of measles. *JAMA.* 1999 Jul 7;282(1):47-53.

*Ratnam S, West R, Gadag V, Burris J.* Measles immunization strategy: measles antibody response following MMR II vaccination of children at one year of age. *Can J Public Health.* 1996 Mar-Apr;87(2):97-100.

*Yuan L.* Measles outbreak in 31 schools: risk factors for vaccine failure and evaluation of a selective revaccination strategy. *CMAJ.* 1994 Apr 1;150(7):1093-8.

*Hutchins SS, Markowitz LE, Mead P, Mixon D, Sheline J, Greenberg N, Preblud SR, Orenstein WA, Hull HF.* A school-based measles outbreak: the effect of a selective revaccination policy and risk factors for vaccine failure. *Am J Epidemiol.* 1990 Jul;132(1):157-68.